Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIN-QUIN vs DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.
Treatment of atrial fibrillation and flutter,Paroxysmal supraventricular tachycardia,Ventricular arrhythmias,Maintenance of sinus rhythm after cardioversion
Pseudobulbar affect (PBA) - FDA approved
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Dextromethorphan: 2-4 hours (extensive metabolizers); quinidine: 6-8 hours (inhibits CYP2D6, prolonging dextromethorphan half-life in poor metabolizers to >20 hours)
Metabolized primarily by CYP3A4 to active metabolites (3-hydroxyquinidine and quinidine-N-oxide).
Dextromethorphan is primarily metabolized by CYP2D6 to dextrorphan; quinidine is a potent CYP2D6 inhibitor at low doses.
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal: quinidine 15-25% unchanged, dextromethorphan <1% unchanged; biliary/fecal: quinidine metabolites ~5%, dextromethorphan metabolites ~60-80% as dextrorphan conjugates
Approximately 70-80% bound, primarily to alpha-1-acid glycoprotein and, to a lesser extent, albumin.
Dextromethorphan: ~60-70% (albumin); quinidine: 80-90% (albumin, alpha-1-acid glycoprotein)
Apparent volume of distribution (Vd) is 1.5-2.5 L/kg, indicating extensive tissue distribution.
Dextromethorphan: 5-6 L/kg; quinidine: 2-3 L/kg
Oral bioavailability is approximately 80% in healthy subjects; may be reduced in patients with malaria due to impaired absorption.
Oral: dextromethorphan ~11% (extensive first-pass metabolism; increased to >50% when coadministered with quinidine); quinidine ~70-80%
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <10 m L/min), reduce dose by one-third to one-half (e.g., 324 mg every 8 hours) and monitor for toxicity.
For creatinine clearance (Cr Cl) 30–59 m L/min: reduce dose to one capsule once daily. For Cr Cl <30 m L/min: not recommended.
No specific guidelines for Child-Pugh classification; use with caution in severe hepatic impairment (Child-Pugh C) and consider dose reduction by 50% based on clinical response and monitoring of serum levels.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: not recommended (quinidine is extensively metabolized by the liver).
For malaria: quinine sulfate 10 mg/kg (base) orally every 8 hours for 7 days (maximum 650 mg/dose) in combination with a second agent.
Safety and efficacy in pediatric patients have not been established; not recommended for use in children.
No specific dose adjustments recommended, but start at lower end of dosing range (e.g., 324 mg every 8 hours) due to age-related renal function decline and increased risk of QT prolongation.
Initiate at one capsule once daily; titrate cautiously. Monitor for QT prolongation and anticholinergic effects. Lower doses may be required due to age-related renal and hepatic decline.
Quinidine has been associated with thrombocytopenic purpura and may exacerbate arrhythmias (proarrhythmia). It should be used with caution in patients with severe heart disease or preexisting arrhythmias.
None.
May cause QT prolongation and torsades de pointes, especially in patients with hypokalemia, hypomagnesemia, or bradycardia,Cinchonism (tinnitus, hearing loss, blurred vision, nausea) may occur at high doses,Hepatic toxicity and hypersensitivity reactions (including thrombocytopenia),Monitor serum potassium and magnesium levels,Avoid use with other drugs that prolong QT interval
CNS depression: may cause dizziness, somnolence; avoid alcohol.,Cardiotoxicity: quinidine may cause QT prolongation; monitor ECG.,Serotonin syndrome: risk with concurrent serotonergic drugs.,Hepatic impairment: use with caution.,Renal impairment: not recommended in severe renal disease.
Hypersensitivity to quinidine or cinchona alkaloids,Complete AV block without pacemaker,Myasthenia gravis,Digitalis toxicity,History of drug-induced torsades de pointes or QT prolongation
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days.,Concomitant use with other drugs that prolong QT interval.,Known hypersensitivity to dextromethorphan or quinidine.,Complete atrioventricular block without pacemaker.,History of drug-induced torsades de pointes.
Avoid grapefruit and grapefruit juice (increases quinidine exposure). Limit caffeine intake as quinidine may enhance its effects. Maintain adequate potassium and magnesium intake; hypokalemia and hypomagnesemia increase arrhythmia risk.
Avoid grapefruit and grapefruit juice as they may increase plasma levels of quinidine, raising risk of toxicity including QT prolongation. Avoid excessive alcohol consumption as it may exacerbate CNS depression.
CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second and third trimesters: may cause fetal hypoxia and hypoglycemia; avoid use for malaria prophylaxis. Only in severe falciparum malaria when no alternative exists.
First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethorphan hydrobromide not associated with major malformations; quinidine sulfate may cause fetal bradycardia and hypoglycemia due to quinidine's antiarrhythmic effects. Overall: No adequate human studies; use only if benefit outweighs risk.
Quinine is excreted into breast milk in small amounts. M/P ratio approximately 0.2-0.5. Limited data suggest low risk to infant; however, monitor for signs of cinchonism (e.g., fever, rash, restlessness).
Dextromethorphan: Likely excreted in breast milk in low amounts; M/P ratio not reported. Quinidine: Excreted in breast milk; M/P ratio approximately 0.71. Potential for infant quinidine toxicity (cinchonism, arrhythmias). Avoid breastfeeding during maternal quinidine therapy.
Pregnancy increases clearance and volume of distribution of quinine; dose adjustments are not well-defined. For severe malaria, standard dosing (600 mg oral quinine sulfate every 8 hours for 7 days) is used, but therapeutic drug monitoring is recommended.
No specific pharmacokinetic studies in pregnancy; increased renal clearance of dextromethorphan in third trimester may lower exposure. For quinidine, plasma protein binding decreases in pregnancy, potentially increasing free drug fraction. Dose adjustment not recommended due to lack of data; titrate based on clinical response and toxicity monitoring.
Cin-Quin is a brand of quinidine, a class Ia antiarrhythmic. Monitor QTc interval; risk of torsades de pointes. Avoid in patients with myasthenia gravis due to neuromuscular blocking effects. Use with caution in hepatic impairment. Can cause cinchonism (tinnitus, headache, nausea).
Monitor for QT prolongation with baseline and periodic ECG, especially in patients with hypokalemia, hypomagnesemia, or bradycardia. Avoid use with CYP3A4 inhibitors (e.g., ketoconazole) or CYP2D6 inhibitors (e.g., paroxetine) due to quinidine metabolism. Quinidine is a potent CYP2D6 inhibitor; caution with concurrent CYP2D6 substrates like tricyclic antidepressants. Onset of pseudobulbar affect improvement may take weeks; titrate dose gradually.
Take exactly as prescribed; do not skip doses or double up.,Report any rapid or irregular heartbeat, fainting, or severe dizziness.,Avoid grapefruit juice as it can increase quinidine levels.,Do not use with over-the-counter products containing quinine or quinidine.,Tell your doctor if you have liver disease, myasthenia gravis, or low potassium/magnesium.,Quinidine can cause diarrhea; contact your doctor if persistent.,You may experience ringing in the ears or blurred vision; notify your prescriber.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid grapefruit juice as it may increase side effects.,Report any signs of irregular heartbeat (palpitations, dizziness, fainting) or allergic reactions (rash, difficulty breathing).,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Do not stop abruptly; dose reduction should be gradual under medical supervision.,Inform all healthcare providers about this medication, especially before any surgery or dental procedure.
No interactions on record
"The coadministration of nisoldipine, a calcium channel blocker, with quinidine, a Class Ia antiarrhythmic, results in a significant reduction in quinidine serum concentrations. This interaction is primarily due to nisoldipine-induced enhancement of hepatic quinidine metabolism via cytochrome P450 3A4 induction, leading to subtherapeutic quinidine levels and potential loss of antiarrhythmic efficacy. Clinically, patients may experience breakthrough arrhythmias or inadequate suppression of atrial or ventricular arrhythmias."
"Scopolamine, an anticholinergic agent, and Quinidine, a Vaughan-Williams Class Ia antiarrhythmic with anticholinergic properties, exhibit additive anticholinergic effects when coadministered. This synergy can lead to enhanced peripheral and central anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, constipation, tachycardia, confusion, and cognitive impairment, particularly in elderly patients. The risk is significant as both drugs block muscarinic acetylcholine receptors, potentially precipitating anticholinergic toxicity."
"Vernakalant, a multi-ion channel blocker primarily used for atrial fibrillation conversion, can inhibit cytochrome P450 (CYP) 3A4, the major enzyme responsible for the metabolism of quinidine. This results in elevated plasma concentrations of quinidine, increasing the risk of quinidine-related cardiotoxicity, including QTc prolongation, torsade de pointes, and other ventricular arrhythmias. The interaction may also potentiate vagolytic effects and negative inotropy, leading to hemodynamic compromise."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIN-QUIN vs DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, answered by our medical review team.
CIN-QUIN is a Antiarrhythmic (Class Ia) that works by Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.. DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is a Antiarrhythmic (Class Ia) that works by Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIN-QUIN and DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIN-QUIN is: Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.. The standard adult dose of DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is: One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIN-QUIN and DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIN-QUIN is classified as Category C. CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second . DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is classified as Category A/B. First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.